Equities

AIM Vaccine Co Ltd

AIM Vaccine Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)6.71
  • Today's Change-0.39 / -5.49%
  • Shares traded8.84m
  • 1 Year change-44.91%
  • Beta--
Data delayed at least 15 minutes, as of Oct 10 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

AIM Vaccine Co Ltd is a China-based company principally engaged in the research and development, manufacturing and sales of vaccine. The Company's products mainly include recombinant hepatitis B vaccine, human rabies vaccine, inactivated hepatitis A vaccine, mumps vaccine, inactivated hemorrhagic fever with renal syndrome vaccine and MPSV4. The Company's products are mainly used for the treatment of hepatitis B, hepatitis A, mumps, hemorrhagic fever with renal syndrome, rabies and meningococcal diseases. The Company's vaccine candidates include messenger RNA (mRNA) corona virus disease 2019 (COVID-19) vaccine, inactivated COVID-19 vaccine, broad-spectrum COVID-19 vaccine, PCV13, PPSV23 and MCV4. The Company principally conducts its businesses in the domestic market.

  • Revenue in HKD (TTM)1.30bn
  • Net income in HKD-1.31bn
  • Incorporated2011
  • Employees1.56k
  • Location
    AIM Vaccine Co Ltd25/FBuilding A, 91 Jianguo Road, ChaoyangBEIJING 110000ChinaCHN
  • Phone+86 1 085950689
  • Fax+86 1 085950063
  • Websitehttps://www.aimbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jiangsu Recbio Technology Co Ltd0.00-602.06m4.30bn507.00--4.64-----1.26-1.260.001.920.00----0.00-25.33---32.84----------0.9619--0.4548------20.86------
Ocumension Therapeutics340.57m-354.21m4.40bn477.00--1.47--12.93-0.5404-0.54040.51944.380.1032.402.48767,048.60-10.71-38.78-11.55-41.4758.2962.30-104.01-975.825.00--0.0055--54.99--5.68--319.66--
Beijing Luzhu Biotechnology Co Ltd0.00-307.25m4.98bn148.00--4.84-----1.52-1.520.005.120.00----0.00-23.80---25.44----------5.91--0.0296------65.62------
Shandong Boan Biotechnology Co Ltd790.07m67.84m5.31bn777.0074.323.3036.866.720.13320.13321.553.000.30691.102.60971,800.902.63--3.43--74.10--8.59--1.034.010.3369--19.80--64.02------
Consun Pharmaceutical Group Ltd3.01bn918.01m6.59bn3.18k6.851.626.562.191.141.143.734.810.52092.0012.89961,378.1015.9712.0423.2419.2574.2274.5530.6624.892.80--0.114440.8410.717.0314.8811.01-22.9318.43
Sihuan Pharmaceutical Holdings Group Ltd1.93bn-41.48m6.90bn2.65k--1.42--3.58-0.0045-0.00450.20750.52070.15060.8943.90670,515.90-1.77-6.85-2.68-9.1065.9175.81-11.78-36.231.50--0.181---14.70-8.6097.23--0.9325--
Tong Ren Tang Technologies Co Ltd7.55bn714.29m7.15bn4.01k10.010.91775.000.94680.55770.55775.896.080.50260.98815.221,840,563.007.427.6811.6912.3240.9743.5014.7616.112.30--0.196839.9413.046.011.25-2.73-22.26-0.0089
Beijing Tong Ren Tang Chinese Medicine1.38bn494.14m7.43bn779.0015.031.9512.015.390.59030.59031.644.550.32840.35543.621,725,133.0012.7216.7114.0918.7572.0669.8838.7240.729.55--0.032768.87-11.910.1459-16.33-1.43-16.307.49
Yichang Hec Changjiang Pharmactcl Co Ltd6.08bn1.81bn7.74bn4.89k4.280.81423.691.272.062.066.9110.810.42722.503.741,316,787.0011.698.0317.2711.8178.9079.9727.3720.801.9350.790.212615.8168.0820.182,501.2416.15-11.50--
Shanghai Fudan-Zhangjiang Bio-Pharm. Co807.84m121.46m7.82bn948.0024.461.13--9.680.11530.11530.75952.500.25041.261.35852,156.303.757.034.669.0591.2592.1714.9717.263.78--0.005239.16-17.502.78-21.28-0.632620.49--
China Shineway Pharmaceutical Group Ltd4.61bn1.21bn8.05bn3.23k6.071.005.801.751.601.606.119.740.44761.285.261,343,072.0011.768.0315.479.7775.2174.5526.2717.873.14--0.045736.2914.3211.9434.1413.890.639612.88
AIM Vaccine Co Ltd1.30bn-1.31bn8.13bn1.56k--2.11--6.25-1.08-1.081.073.180.14620.63251.10800,318.30-22.69---37.16--72.34---155.22--0.6836-6.610.3437---6.06---307.07------
Everest Medicines Ltd459.39m-1.16bn8.28bn520.00--1.69--18.02-3.59-3.591.4215.090.07565.233.221,063,409.00-19.03-30.52-20.21-33.1475.74---251.64-5,745.254.62--0.1119--884.46---241.50--4.65--
Cansino Biologics Inc668.99m-951.24m10.69bn1.49k--1.16--15.97-3.85-3.852.7122.480.06761.280.8385447,782.40-10.15-4.27-13.73-5.6014.38---150.19-27.722.19--0.3028---66.52213.94-63.04--30.60--
Data as of Oct 10 2024. Currency figures normalised to AIM Vaccine Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

7.12%Per cent of shares held by top holders
HolderShares% Held
China Merchants Wealth Asset Management Ltd.as of 19 Oct 202330.36m6.17%
GF Fund Management Co., Ltd.as of 31 Dec 20232.45m0.50%
BlackRock Fund Advisorsas of 04 Jul 20241.05m0.21%
China Asset Management (Hong Kong) Ltd.as of 28 Jun 2024347.84k0.07%
Bosera Asset Management Co., Ltd.as of 31 Dec 2023236.80k0.05%
TIAA-CREF Investment Management LLCas of 30 Jun 2024166.60k0.03%
Dimensional Fund Advisors LPas of 30 Apr 2024139.60k0.03%
SSgA Funds Management, Inc.as of 03 Jul 2024133.40k0.03%
BlackRock Advisors (UK) Ltd.as of 04 Jul 202487.80k0.02%
China Asset Management Co., Ltd.as of 31 Dec 202367.00k0.01%
More ▼
Data from 31 Dec 2023 - 07 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.